JP5107578B2 - ボツリヌス毒素治療 - Google Patents
ボツリヌス毒素治療 Download PDFInfo
- Publication number
- JP5107578B2 JP5107578B2 JP2006541996A JP2006541996A JP5107578B2 JP 5107578 B2 JP5107578 B2 JP 5107578B2 JP 2006541996 A JP2006541996 A JP 2006541996A JP 2006541996 A JP2006541996 A JP 2006541996A JP 5107578 B2 JP5107578 B2 JP 5107578B2
- Authority
- JP
- Japan
- Prior art keywords
- bladder
- botulinum toxin
- balloon
- solid
- formulation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 108030001720 Bontoxilysin Proteins 0.000 title claims abstract description 88
- 229940053031 botulinum toxin Drugs 0.000 title claims abstract description 71
- 239000000203 mixture Substances 0.000 claims abstract description 45
- 238000009472 formulation Methods 0.000 claims abstract description 39
- 239000007787 solid Substances 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 23
- 239000007788 liquid Substances 0.000 claims abstract description 22
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 11
- 238000002347 injection Methods 0.000 claims abstract description 11
- 239000007924 injection Substances 0.000 claims abstract description 11
- 208000035475 disorder Diseases 0.000 claims abstract description 10
- 210000005070 sphincter Anatomy 0.000 claims abstract description 10
- 206010048994 Bladder spasm Diseases 0.000 claims abstract description 6
- 206010046543 Urinary incontinence Diseases 0.000 claims abstract description 5
- 206010020853 Hypertonic bladder Diseases 0.000 claims abstract description 4
- 206010046555 Urinary retention Diseases 0.000 claims abstract description 4
- 208000018737 Parkinson disease Diseases 0.000 claims abstract description 3
- 206010037211 Psychomotor hyperactivity Diseases 0.000 claims abstract description 3
- 208000006011 Stroke Diseases 0.000 claims abstract description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims abstract description 3
- 208000020431 spinal cord injury Diseases 0.000 claims abstract description 3
- 230000011514 reflex Effects 0.000 claims abstract 2
- 239000012669 liquid formulation Substances 0.000 claims description 6
- 230000002920 convulsive effect Effects 0.000 claims description 4
- 230000027939 micturition Effects 0.000 claims description 3
- 230000000926 neurological effect Effects 0.000 claims description 3
- 206010020880 Hypertrophy Diseases 0.000 claims description 2
- 238000000034 method Methods 0.000 abstract description 16
- 238000002360 preparation method Methods 0.000 abstract description 15
- 238000001802 infusion Methods 0.000 abstract description 5
- 208000005392 Spasm Diseases 0.000 abstract description 2
- 230000001148 spastic effect Effects 0.000 abstract description 2
- 208000000693 Neurogenic Urinary Bladder Diseases 0.000 abstract 1
- 206010029279 Neurogenic bladder Diseases 0.000 abstract 1
- 230000004064 dysfunction Effects 0.000 abstract 1
- 210000003932 urinary bladder Anatomy 0.000 description 55
- 108010057266 Type A Botulinum Toxins Proteins 0.000 description 16
- 229940094657 botulinum toxin type a Drugs 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 15
- 102000004169 proteins and genes Human genes 0.000 description 15
- 239000003053 toxin Substances 0.000 description 12
- 231100000765 toxin Toxicity 0.000 description 12
- 108700012359 toxins Proteins 0.000 description 12
- 239000007921 spray Substances 0.000 description 10
- 239000000499 gel Substances 0.000 description 9
- 230000035515 penetration Effects 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 241000193155 Clostridium botulinum Species 0.000 description 7
- 108010074523 rimabotulinumtoxinB Proteins 0.000 description 7
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- 231100001103 botulinum neurotoxin Toxicity 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 231100000252 nontoxic Toxicity 0.000 description 6
- 230000003000 nontoxic effect Effects 0.000 description 6
- 230000000890 antigenic effect Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000000626 ureter Anatomy 0.000 description 5
- 239000010410 layer Substances 0.000 description 4
- 239000002581 neurotoxin Substances 0.000 description 4
- 231100000618 neurotoxin Toxicity 0.000 description 4
- 230000002797 proteolythic effect Effects 0.000 description 4
- 208000003508 Botulism Diseases 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 101710138657 Neurotoxin Proteins 0.000 description 3
- 108010079650 abobotulinumtoxinA Proteins 0.000 description 3
- 239000002260 anti-inflammatory agent Substances 0.000 description 3
- 229940121363 anti-inflammatory agent Drugs 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 229940098753 dysport Drugs 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 101710154606 Hemagglutinin Proteins 0.000 description 2
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 2
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 241000288906 Primates Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 101710176177 Protein A56 Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 2
- 229960004373 acetylcholine Drugs 0.000 description 2
- 238000002399 angioplasty Methods 0.000 description 2
- 239000003699 antiulcer agent Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004880 explosion Methods 0.000 description 2
- 238000000855 fermentation Methods 0.000 description 2
- 239000003966 growth inhibitor Substances 0.000 description 2
- 229960004716 idoxuridine Drugs 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- DEQANNDTNATYII-OULOTJBUSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-19-[[(2r)-2-amino-3-phenylpropanoyl]amino]-16-benzyl-n-[(2r,3r)-1,3-dihydroxybutan-2-yl]-7-[(1r)-1-hydroxyethyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-1,2-dithia-5,8,11,14,17-pentazacycloicosane-4-carboxa Chemical compound C([C@@H](N)C(=O)N[C@H]1CSSC[C@H](NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](CC=2C3=CC=CC=C3NC=2)NC(=O)[C@H](CC=2C=CC=CC=2)NC1=O)C(=O)N[C@H](CO)[C@H](O)C)C1=CC=CC=C1 DEQANNDTNATYII-OULOTJBUSA-N 0.000 description 1
- PUDHBTGHUJUUFI-SCTWWAJVSA-N (4r,7s,10s,13r,16s,19r)-10-(4-aminobutyl)-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]-19-[[(2r)-2-amino-3-naphthalen-2-ylpropanoyl]amino]-16-[(4-hydroxyphenyl)methyl]-13-(1h-indol-3-ylmethyl)-6,9,12,15,18-pentaoxo-7-propan-2-yl-1,2-dithia-5,8,11,14,17-p Chemical compound C([C@H]1C(=O)N[C@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](N)CC=1C=C2C=CC=CC2=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(N)=O)=O)C(C)C)C1=CC=C(O)C=C1 PUDHBTGHUJUUFI-SCTWWAJVSA-N 0.000 description 1
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 206010056948 Automatic bladder Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 208000004095 Hemifacial Spasm Diseases 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 208000034819 Mobility Limitation Diseases 0.000 description 1
- 208000007101 Muscle Cramp Diseases 0.000 description 1
- 208000012902 Nervous system disease Diseases 0.000 description 1
- 208000025966 Neurological disease Diseases 0.000 description 1
- 108010016076 Octreotide Proteins 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010010469 Qa-SNARE Proteins Proteins 0.000 description 1
- 208000004350 Strabismus Diseases 0.000 description 1
- 101000874347 Streptococcus agalactiae IgA FC receptor Proteins 0.000 description 1
- 102000050389 Syntaxin Human genes 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000002491 angiogenic effect Effects 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000003124 biologic agent Substances 0.000 description 1
- 208000029162 bladder disease Diseases 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 108010069022 botulinum toxin type D Proteins 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 230000001713 cholinergic effect Effects 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000011247 coating layer Substances 0.000 description 1
- 230000036461 convulsion Effects 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000002574 cystoscopy Methods 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000002498 deadly effect Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- SUBDBMMJDZJVOS-DEOSSOPVSA-N esomeprazole Chemical compound C([S@](=O)C1=NC2=CC=C(C=C2N1)OC)C1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-DEOSSOPVSA-N 0.000 description 1
- 229960004770 esomeprazole Drugs 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 210000001508 eye Anatomy 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000001415 gene therapy Methods 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 239000003721 gunpowder Substances 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 108010021336 lanreotide Proteins 0.000 description 1
- 229960002437 lanreotide Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000005226 mechanical processes and functions Effects 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002161 motor neuron Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940112646 myobloc Drugs 0.000 description 1
- 208000018360 neuromuscular disease Diseases 0.000 description 1
- 210000000715 neuromuscular junction Anatomy 0.000 description 1
- 230000000720 neurosecretory effect Effects 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 229960002700 octreotide Drugs 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003961 penetration enhancing agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 235000013324 preserved food Nutrition 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 238000002601 radiography Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 208000037803 restenosis Diseases 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical class C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000009747 swallowing Effects 0.000 description 1
- 210000003568 synaptosome Anatomy 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 238000011287 therapeutic dose Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 208000026533 urinary bladder disease Diseases 0.000 description 1
- 208000014001 urinary system disease Diseases 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A61K38/4893—Botulinum neurotoxin (3.4.24.69)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/06—Anti-spasmodics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0328060.9 | 2003-12-04 | ||
| GBGB0328060.9A GB0328060D0 (en) | 2003-12-04 | 2003-12-04 | Botulinum toxin treatment |
| PCT/GB2004/004770 WO2005053733A1 (en) | 2003-12-04 | 2004-11-12 | Botulinum toxin treatment of spastic bladder |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2007513127A JP2007513127A (ja) | 2007-05-24 |
| JP2007513127A5 JP2007513127A5 (https=) | 2007-12-27 |
| JP5107578B2 true JP5107578B2 (ja) | 2012-12-26 |
Family
ID=29764527
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006541996A Expired - Fee Related JP5107578B2 (ja) | 2003-12-04 | 2004-11-12 | ボツリヌス毒素治療 |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20070275110A1 (https=) |
| EP (1) | EP1691828B1 (https=) |
| JP (1) | JP5107578B2 (https=) |
| AT (1) | ATE475429T1 (https=) |
| CA (1) | CA2547618C (https=) |
| DE (1) | DE602004028403D1 (https=) |
| DK (1) | DK1691828T3 (https=) |
| ES (1) | ES2347151T3 (https=) |
| GB (1) | GB0328060D0 (https=) |
| PL (1) | PL1691828T3 (https=) |
| PT (1) | PT1691828E (https=) |
| RU (1) | RU2350348C2 (https=) |
| WO (1) | WO2005053733A1 (https=) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2879462B1 (fr) * | 2004-12-21 | 2008-12-26 | Sod Conseils Rech Applic | Utilisation de toxine botulique pour une insensibilisation locale prolongee |
| ES2509872T3 (es) | 2005-03-03 | 2014-10-20 | Allergan, Inc. | Procedimientos para obtener una toxina clostrídica |
| US20090304747A1 (en) * | 2006-05-16 | 2009-12-10 | Mayo Foundation For Medical Education And Research | Use of dmso and botulinum toxin therapy for urinary incontinence and related disorders |
| CA2678038C (en) | 2007-02-15 | 2016-10-11 | Allergan, Inc. | Use of botulinum toxin and enzymes for treating bladder or prostate disorders, or hyperhydrosis |
| MX2010004502A (es) | 2007-10-23 | 2010-06-17 | Allergan Inc | Metodos para tratar trastornos neurologicos urogenitales usando toxinas clostridiales modificadas. |
| US10471150B2 (en) | 2010-01-20 | 2019-11-12 | Urogen Pharma Ltd. | Material and method for treating internal cavities |
| WO2011089604A2 (en) | 2010-01-20 | 2011-07-28 | Theracoat Ltd | Material and method for treating internal cavities |
| US20130171122A1 (en) * | 2011-12-29 | 2013-07-04 | Allergan, Inc. | Endopeptidase and neurotoxin combination treatment of bladder disorders |
| RU2635466C2 (ru) * | 2012-04-08 | 2017-11-13 | Теракоат Лтд | Препараты термообратимого гидрогеля для применения при лечении нарушений уротелия |
| JP2017532301A (ja) * | 2014-09-24 | 2017-11-02 | ウェルズリー ファーマスーティカルズ、エルエルシー | 膀胱痙攣を低減するための医薬製剤およびその使用の方法 |
| RU2605624C1 (ru) * | 2015-11-23 | 2016-12-27 | Государственное бюджетное образовательное учреждение высшего профессионального образования "Санкт-Петербургский государственный педиатрический медицинский университет" Министерства здравоохранения Российской Федерации (ГБОУ ВПО СПбГПМУ Минздрава России) | Способ лечения детрузорной гиперактивности |
| KR102480965B1 (ko) | 2016-09-13 | 2022-12-26 | 알레간 인코포레이티드 | 안정화된 비단백질 클로스트리듐 독소 조성물 |
| TWI810228B (zh) | 2017-12-20 | 2023-08-01 | 英商艾普森生物製藥有限公司 | 自主神經系統障礙之治療 |
| CA3201129A1 (en) | 2020-12-11 | 2022-06-16 | Yulia HIONIDI | Material and method for treating cancer |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5236956A (en) * | 1988-11-04 | 1993-08-17 | Kabi Pharmacia Aktiebolag | Compounds for the treatment of urinary incontinence |
| SE8804003D0 (sv) * | 1988-11-04 | 1988-11-04 | Pharmacia Ab | Compounds for the treatment of urinary incontinence |
| JPH0564661A (ja) * | 1991-09-09 | 1993-03-19 | Olympus Optical Co Ltd | 体腔内挿入具 |
| US5437291A (en) * | 1993-08-26 | 1995-08-01 | Univ Johns Hopkins | Method for treating gastrointestinal muscle disorders and other smooth muscle dysfunction |
| US5749845A (en) | 1995-01-25 | 1998-05-12 | Iotek, Inc. | Delivering an agent to an organ |
| KR100544060B1 (ko) * | 1997-07-15 | 2006-01-23 | 더 리젠트스 오브 더 유니버시티 오브 콜로라도 | 비뇨기과학 및 관련 부전증을 치료하기 위한 신경독요법의 용도 |
| US6630570B1 (en) * | 1999-04-09 | 2003-10-07 | Insitut für Diagnostikforschung GmbH | Short-chain peptide-dye conjugates as contrast media for optical diagnosis |
| DE19917713A1 (de) * | 1999-04-09 | 2000-10-19 | Diagnostikforschung Inst | Kurzkettige Peptid-Farbstoffkonjugate als Konstrastmittel für die optische Diagnostik |
| US6579847B1 (en) * | 2000-05-01 | 2003-06-17 | Imarx Therapeutics Inc. | Method and apparatus for vascular neuromuscular blockade |
| US6306423B1 (en) * | 2000-06-02 | 2001-10-23 | Allergan Sales, Inc. | Neurotoxin implant |
| US6638246B1 (en) * | 2000-11-28 | 2003-10-28 | Scimed Life Systems, Inc. | Medical device for delivery of a biologically active material to a lumen |
| US20020099356A1 (en) * | 2001-01-19 | 2002-07-25 | Unger Evan C. | Transmembrane transport apparatus and method |
| DK1411978T3 (da) * | 2001-07-27 | 2009-01-05 | Univ Louisiana State | Botulinum-toksin ved behandlingen eller forebyggelsen af acne |
| AU2002323151A1 (en) * | 2001-08-13 | 2003-03-03 | University Of Pittsburgh | Application of lipid vehicles and use for drug delivery |
| WO2003061626A1 (en) * | 2002-01-18 | 2003-07-31 | Control Delivery Systems, Inc. | Polymeric gel system for the controlled delivery of codrugs |
| US20040067235A1 (en) * | 2002-07-29 | 2004-04-08 | Rajiv Doshi | Methods for the use of neurotoxin in the treatment of urologic disorders |
-
2003
- 2003-12-04 GB GBGB0328060.9A patent/GB0328060D0/en not_active Ceased
-
2004
- 2004-11-12 EP EP04798493A patent/EP1691828B1/en not_active Revoked
- 2004-11-12 ES ES04798493T patent/ES2347151T3/es not_active Expired - Lifetime
- 2004-11-12 DE DE602004028403T patent/DE602004028403D1/de not_active Expired - Lifetime
- 2004-11-12 AT AT04798493T patent/ATE475429T1/de active
- 2004-11-12 JP JP2006541996A patent/JP5107578B2/ja not_active Expired - Fee Related
- 2004-11-12 US US10/581,671 patent/US20070275110A1/en not_active Abandoned
- 2004-11-12 WO PCT/GB2004/004770 patent/WO2005053733A1/en not_active Ceased
- 2004-11-12 RU RU2006123561/15A patent/RU2350348C2/ru not_active IP Right Cessation
- 2004-11-12 PL PL04798493T patent/PL1691828T3/pl unknown
- 2004-11-12 CA CA2547618A patent/CA2547618C/en not_active Expired - Fee Related
- 2004-11-12 DK DK04798493.5T patent/DK1691828T3/da active
- 2004-11-12 PT PT04798493T patent/PT1691828E/pt unknown
-
2008
- 2008-05-29 US US12/155,104 patent/US8277822B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| EP1691828B1 (en) | 2010-07-28 |
| JP2007513127A (ja) | 2007-05-24 |
| WO2005053733A1 (en) | 2005-06-16 |
| US20070275110A1 (en) | 2007-11-29 |
| RU2350348C2 (ru) | 2009-03-27 |
| CA2547618C (en) | 2014-05-27 |
| DE602004028403D1 (de) | 2010-09-09 |
| PL1691828T3 (pl) | 2011-01-31 |
| DK1691828T3 (da) | 2010-11-01 |
| EP1691828A1 (en) | 2006-08-23 |
| ATE475429T1 (de) | 2010-08-15 |
| ES2347151T3 (es) | 2010-10-26 |
| RU2006123561A (ru) | 2008-01-10 |
| US20090028907A1 (en) | 2009-01-29 |
| GB0328060D0 (en) | 2004-01-07 |
| CA2547618A1 (en) | 2005-06-16 |
| PT1691828E (pt) | 2010-10-04 |
| US8277822B2 (en) | 2012-10-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US8277822B2 (en) | Botulinum toxin treatment | |
| KR101041698B1 (ko) | 경피성 보툴리눔 독소 조성물 | |
| ES2281636T3 (es) | Uso de toxina botulinica para tratar enfermedades cardiovasculares. | |
| ES2441961T3 (es) | Composiciones de toxina botulínica y métodos | |
| KR20030009431A (ko) | 신경독의 말초 투여를 통한 동통 처치 방법 | |
| ES2393217T3 (es) | Métodos para el tratamiento de una estenosis de uretra con una toxina botulínica | |
| JP2010222367A (ja) | 持続勃起症を処置するためのボツリヌス毒素 | |
| CZ200523A3 (cs) | Způsob zamezení okluze v zavedeném katétru za použití fibrinolytických metalloproteinas | |
| WO2017179775A1 (en) | Microstructure formulation techniques for botulinum toxin | |
| JP2007517890A (ja) | 血管障害の処置方法 | |
| CN111491659A (zh) | 用肉毒杆菌毒素治疗自主神经疾病 | |
| US10792400B2 (en) | Microstructure formulation techniques for botulinum toxin | |
| ES2242655T3 (es) | Uso de metaloproteinasas fibrinoliticas para el tratamiento terapeutico de coagulos de sangre. | |
| CN109646673A (zh) | 肉毒杆菌毒素的微结构制剂技术 | |
| US10525111B2 (en) | Microstructure formulation techniques for botulinum toxin | |
| EP3470054B1 (en) | Microstructure formulation techniques for botulinum toxin | |
| HK40007558A (en) | Microstructure formulation techniques for botulinum toxin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071109 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071109 |
|
| A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20100705 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20100705 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101019 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20110107 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20110117 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20110407 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20111115 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120131 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20120904 |
|
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20121004 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5107578 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20151012 Year of fee payment: 3 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |